Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 15/20 | 0.41 |
| ▸ | HTR1A | P08908 | 11/20 | 0.38 |
| ▸ | HTR1B | P28222 | 9/20 | 0.36 |
| ▸ | HTR1D | P28221 | 8/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8724084 | 0.81 | HTR1F (0.60) | HTR1FHTR1AHTR1BHTR1D | |
| SCHEMBL8385515 | 0.81 | HTR1F (0.44) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8385510 | 0.79 | HTR1F (0.59) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8385395 | 0.78 | HTR1F (0.53) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8381571 | 0.78 | HTR1F (0.56) | HTR1FHTR1AHTR1BHTR1D | |
| SCHEMBL8381812 | 0.77 | HTR1F (0.63) | HTR1FHTR1AHTR1BHTR1D | |
| SCHEMBL8386631 | 0.77 | HTR1F (0.56) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8385487 | 0.76 | HTR1F (0.45) | HTR1FHTR1AHTR1BHTR1DJAK1 | |
| SCHEMBL8383688 | 0.76 | HTR1F (0.49) | HTR1FHTR1AHTR1BHTR1D | |
| SCHEMBL8385333 | 0.75 | HTR1F (0.40) | HTR1FHTR1AHTR1BHTR1DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| US-5874427-A | MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1F 1/4885HTR1A 2/4885HTR1B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.